Where does oxaliplatin fit in the treatment paradigm for advanced metastatic pancreatic cancer?

FAQ Library published on September 11, 2017
Download Transcript Download Audio
Ramesh K. Ramanathan, MD
Director, GI Medical Oncology
Vice Chair of Research
Division of Hematology/Oncology
Mayo Clinic
Phoenix, Arizona
Where does oxaliplatin fit in the treatment paradigm for advanced metastatic pancreatic cancer?

Welcome to Partners in Pancreatic Cancer. I am Dr. Ramesh Ramanathan from the Mayo Clinic in Phoenix, Arizona. I am frequently asked, “Where does oxaliplatin fit in the treatment paradigm for advanced pancreatic cancer?”

Oxaliplatin in combination with 5-FU, in the U.S. is the FOLFOX regimen; it is frequently used as a second-line regimen. Recently, based on a clinical trial from Canada, the NCIC study compared 5-FU by 4- to 6-hour infusion to a modified FOLFOX regimen. This regimen is no longer widely used, and the reason is because the results of this study showed that oxaliplatin with 5-FU did not improve the outcomes, and in fact had more toxicity. This is supported by a meta-analysis from my colleagues at Mayo Clinic who looked at second-line therapy in combination with 5-FU of oxaliplatin or irinotecan where oxaliplatin did not improve overall survival. We now have an effective second-line regimen which is 5-FU and MM-398, or ONIVYDE, and I think that is a better second-line regimen than FOLFOX. Most patients who have second-line therapy typically will have FOLFIRINOX, or gemcitabine and nab-paclitaxel and also have some baseline neuropathy where oxaliplatin is suitable. I think, in conclusion, oxaliplatin has a diminishing role as second-line therapy. Thank you for viewing this activity.

Last modified: July 24, 2017
Related Items by Author
Will immunotherapy have a future role in advanced pancreatic cancer?
Ramesh K. Ramanathan, MD
FAQ Library published on July 10, 2017

Partners in Pancreatic Cancer would like to recognize and thank Celgene Corporation
for their educational support of PartnersinPancreaticCancer.com.

©2017 MediCom Worldwide, Inc. All rights reserved